For the readers interested in the stock health of Clovis Oncology Inc. (CLVS). It is currently valued at $6.90. When the transactions were called off in the previous session, Stock hit the highs of $7.35, after setting-off with the price of $7.08. Company’s stock value dipped to $6.8601 during the trading on the day. When the trading was stopped its value was $7.05.
Recently in News on March 19, 2021, Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation. Data from the randomized, Phase 3 ARIEL4 study to be presented today at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Clovis Oncology Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $11.10 on 02/08/21, with the lowest value was $4.73 for the same time period, recorded on 01/06/21.
Clovis Oncology Inc. (CLVS) full year performance was 13.11%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Clovis Oncology Inc. shares are logging -37.84% during the 52-week period from high price, and 69.12% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $4.08 and $11.10.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4337088 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Clovis Oncology Inc. (CLVS) recorded performance in the market was 43.75%, having the revenues showcasing 43.45% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 724.36M, as it employees total of 429 workers.
Analysts verdict on Clovis Oncology Inc. (CLVS)
During the last month, 0 analysts gave the Clovis Oncology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 6.01, with a change in the price was noted +2.73. In a similar fashion, Clovis Oncology Inc. posted a movement of +65.47% for the period of last 100 days, recording 10,619,552 in trading volumes.
Clovis Oncology Inc. (CLVS): Technical Analysis
Raw Stochastic average of Clovis Oncology Inc. in the period of last 50 days is set at 30.69%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 43.99%. In the last 20 days, the company’s Stochastic %K was 47.32% and its Stochastic %D was recorded 48.91%.
Let’s take a glance in the erstwhile performances of Clovis Oncology Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 43.75%. Additionally, trading for the stock in the period of the last six months notably improved by 20.00%, alongside a boost of 13.11% for the period of the last 12 months. The shares increased approximately by 9.18% in the 7-day charts and went down by 23.66% in the period of the last 30 days. Common stock shares were driven by 43.45% during last recorded quarter.